Iterum Therapeutics plc (ITRMF) Free cash flow 2017–2024
Iterum Therapeutics plc (ITRMF) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$26.8MFY2024 · since FY2017: -$31.4M → -$26.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -$26.8M | +32.0% |
| FY2023 | -$39.3M | -112.3% |
| FY2022 | -$18.5M | -16.6% |
| FY2021 | -$15.9M | +70.8% |
| FY2020 | -$54.5M | +33.4% |
| FY2019 | -$81.9M | -6.0% |
| FY2018 | -$77.3M | -146.2% |
| FY2017 | -$31.4M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice